Page  1  PHILLIP SECURITIES (HK) RESEARCH
雲南白藥 (000538SZ)
29 JUNE 2018
近期市場波動加劇，公司股價回落，出現買入機會。我們重申公司基本面情況良好，
一季度營業收入同比增長726%，淨利潤同比增速1118%，經營活動產生的現金淨流量
同比增加13775%。公司銷售人效在混改後改善明顯。同時，建議關注公司醫療業務進
展。我們預測2018年EPS為34元股，維持33倍目標市盈率，目標股價1120元。(現價
行業增速放緩，惟龍頭強者恒強
惟龍頭強者恒強。中國商務部發佈的2017 年藥品流通行業運行統計
分析報告顯示，醫藥批發企業增速放緩，前100 位藥品批發企業主營業務收入同比
增長84%，下降56 個百分點。雲南省醫藥公司的批發業務年營收1449 億元，在藥
品批發企業排名中，名列第16 位，是區域龍頭流通企業。未來，國家各項醫改政策相
繼發佈實施，藥品流通行業將進入深度調整期，區域性藥品流通企業將加速跨區域並
混改之後銷售人員效率提升。2010-2016年，銷售人員人均效率有所下降。2017年，公
司控股股東雲南白藥控股有限公司引進民營企業新華都和江蘇魚躍作為戰略投資者，
進一步加深混合所有制改革。2017年銷售人員效率已見提高，銷售人員人均收入貢獻
同比上升962%（2016年增速419%），人均淨利潤同比增速達到238%（2016年增速
16%）。隨著混改效果進一步顯現，預計公司有望保持良好的運營效率。
圖表：銷售人員人均貢獻（萬元）
工業收入人均貢獻萬元
流通收入人均貢獻萬元
Source Company Phillip Securities
療業務值得期待。公司公佈的投資者訪談顯示，順應雲南省要把雲南建設成健康生
活目的地的地區戰略，公司作為雲南省和昆明市的龍頭醫藥健康企業，有望得到政府
政策的支援和傾斜。公司拓展醫療業務的思路包括，尋找例如高等院校端的醫療資
源，或結合白藥的品牌特點，向骨傷科診療方向拓展。建議關注相關進展。
現價 RMB10403
(現價截至6 月27 日)
目標價 RMB1120 (766%)
普通股股東 (百萬股) 
市值 (人民幣百萬元) 
52 周 最高價最低價 (人民幣) 
Yunnan Baiyao Holdings
Source Aastocks Phillip Securities (HK) Research
Source Wind Phillip Securities Est
Page  2  PHILLIP SECURITIES (HK) RESEARCH
雲南白藥 (000538SZ)
我們的模型顯示目標價為1120元。我們預測未來各分部業務增速，假設2018年
EPS預測至34元股，維持33倍目標市盈率，目標股價1120元。風險包括
費用上升；流通業務受兩票制影響；健康產品競爭激烈；混改效果不及預期。
圖表：業務分部收入、增速及假設(RMB000)
Source Company Phillip Securities
MktCapmn ROE(%)
000538SZ 雲南白藥
600518SH 康美藥業
600436SH 片仔癀
600332SH 白雲山
600085SH 同仁堂
600566SH 濟川藥業
600535SH 天士力
002773SZ 康弘藥業
000423SZ 東阿阿膠
603858SH 步長製藥
Page  3  PHILLIP SECURITIES (HK) RESEARCH
雲南白藥 (000538SZ)
Source Wind (as at Jun 27) Phillip Securities
Page  4  PHILLIP SECURITIES (HK) RESEARCH
雲南白藥 (000538SZ)
Price to Earnings (PE)
Price to Book (PB)
Per Share Data (RMB)
Growth (%)
Margins (%)
Operating Profit Margin
- Cost of Goods Sold
- Operating Expenses
 Net Non-Operating GainLoss
- Minority Interest
Source Company Wind Phillip Securities (HK) Research Estimates
(財務資料截至2018 年6 月27 日)
雲南白藥 (000538SZ)
PHILLIP RESEARCH STOCK SELECTION SYSTEMS
risk reward profile market sentiment recent rate of share price appreciation presence or absence of stock price catalysts and speculative undertones
This publication is prepared by Phillip Securities (Hong Kong) Ltd (Phillip Securities) By receiving or reading this publication you agree to be bound by the terms and
limitations set out below
This publication shall not be reproduced in whole or in part distributed or published by you for any purpose Phillip Securities shall not be liable for any direct or
consequential loss arising from any use of material contained in this publication
The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis
forecasts projections expectations and opinions (collectively the Research) contained in this publication are based on such information and are expressions of belief only
verified or should be relied upon as such Any such information or Research contained in this publication is subject to change and Phillip Securities shall not have any
responsibility to maintain the information or Research made available or to supply any corrections updates or releases in connection therewith In no event will Phillip
Securities be liable for any special indirect incidental or consequential damages which may be incurred from the use of the information or Research made available even
if it has been advised of the possibility of such damages
Any opinions forecasts assumptions estimates valuations and prices contained in this material are as of the date indicated and are subject to change at any time without
prior notice
This material is intended for general circulation only and does not take into account the specific investment objectives financial situation or particular needs of any
particular person The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a
financial adviser regarding the suitability of such products taking into account the specific investment objectives financial situation or particular needs of that person
This publication should not be relied upon as authoritative without further being subject to the recipients own independent verification and exercise of judgment The fact
this material is suitable or appropriate for the recipient Recipients should be aware that many of the products which may be described in this publication involve significant
risks and may not be suitable for all investors and that any decision to enter into transactions involving such products should not be made unless all such risks are
understood and an independent determination has been made that such transactions would be appropriate Any discussion of the risks contained herein with respect to any
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security Any decision to purchase securities mentioned in this research
should take into account existing public information including any registered prospectus in respect of such security
Disclosure of Interest
Analyst Disclosure Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this
Firms Disclosure Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or
more of the market capitalization in the listed corporation In addition no executive staff of Phillip Securities serves as an officer of the listed corporation
The information tools and material presented herein are not directed intended for distribution to or use by any person or entity in any jurisdiction or country where such
distribution publication availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or licensing or
other requirement or penalty for contravention of such requirements within such jurisdiction
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited (PSHK) believed to be accurate PSHK does not bear responsibility for any
loss occasioned by reliance placed upon the contents hereof  PSHK (or its affiliates or employees) may have positions in relevant investment products For details of
2018 Phillip Securities (Hong Kong) Limited
Contact Information (Regional Member Companies)
20% upside from the current price
5% to 20%
5% to 20%upside from the current price
-5% to 5%
Trade within   5% from the current price
-5% to -20%
-5% to -20% downside from the current price
20%downside from the current price
雲南白藥 (000538SZ)
Phillip Securities Pte Ltd
250 North Bridge Road 06-00
Singapore 179101
Tel  (65) 6533 6001
Fax  (65) 6535 6631
Phillip Capital Management Sdn Bhd
B-3-6 Block B Level 3 Megan Avenue II
No 12 Jalan Yap Kwan Seng 50450
Phillip Securities (HK) Ltd
Exchange Participant of the Stock Exchange of Hong Kong
11F United Centre 95 Queensway
PhillipCapital Japan KK
Nagata-cho Bldg
8F 2-4-3 Nagata-cho
Chiyoda-ku Tokyo 100-0014
PT Phillip Securities Indonesia
ANZ Tower Level 23B
Jl Jend Sudirman Kav 33A
Jakarta 10220  Indonesia
Phillip Financial Advisory (Shanghai) Co Ltd
No 436 Hengfeng Road
Greentech Unit 604
Postal code 200070
Phillip Securities (Thailand) Public Co Ltd
15th Floor Vorawat Building
849 Silom Road Silom Bangrak
Bangkok 10500 Thailand
King  Shaxson Capital Limited
3rd Floor 35 Rue de la Bienfaisance 75008
King  Shaxson Capital Limited
6th Floor Candlewick House
120 Cannon Street
London EC4N 6AS
141 W Jackson Blvd Ste 3050
The Chicago Board of Trade Building
Chicago IL 60604 USA
PhillipCapital Australia
Level 12 15 William Street
Melbourne Victoria 3000 Australia